Announced
Financials
Sources
Tags
biotechnology
Acquisition
Pending
Domestic
Majority
Single Bidder
United States
Biotechnology
Private
Friendly
Private Equity
Synopsis
Eli Lilly, a global healthcare company, agreed to acquire Disarm Therapeutics, a biotechnology company, from private equity firms Atlas Venture, Biogenerator, and Lightstone Ventures, for $135m. "Disarm's innovative approach to treating axonal degeneration holds tremendous promise for addressing a wide spectrum of neurological diseases, and we have made significant strides toward enabling potentially transformative therapies. Lilly is ideally suited to advance this exciting new approach to treating axonal degeneration, and we look forward to seeing patients benefit from the work that Disarm initiated," Alvin Shih, Disarm Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.